What were the results of the study?
In cancer treatment studies, researchers want to know how many patients respond to therapy. This is measured as overall response, or the percentage of patients whose tumors either shrank by at least 30% or completely disappeared. Every individual is different and may respond differently.
TAZVERIK was studied in a clinical trial of 62 patients with epithelioid sarcoma that had spread or grown and could not be removed by surgery:
*The time to tumor shrinkage in the clinical trial ranged from around 1 month to around 18 months.
†The overall response is the sum of partial responses and complete responses. It means the tumor either reduced in size by at least 30% or completely disappeared.
It is important that you are informed about the possible side effects during treatment with TAZVERIK.
Talk to your doctor about concerns you may have.
What is the most important information I should know about TAZVERIK?
TAZVERIK can cause serious side effects, including:
- Risk of new cancers. An increase in new (second) cancers has happened in people who were treated with TAZVERIK. Talk with your healthcare provider about your risk of developing new cancers. Your healthcare provider will monitor you for new cancers after your treatment with TAZVERIK. Tell your healthcare provider if you are more tired than usual, or have easy bruising, fever, bone pain, or paleness.
What are the possible side effects of TAZVERIK?
The most common side effects of TAZVERIK in people with epithelioid sarcoma include:
- Decreased appetite
These are not all of the possible side effects of TAZVERIK. Tell your healthcare provider right away if you have any side effect that bothers you or that does not go away.
You are encouraged to report side effects of prescription drugs to Ipsen Biopharmaceuticals, Inc. at 1-855-463-5127 or to the FDA at 1-800-FDA-1088 or www.fda.gov/medwatch.